Deutsche Bank Has Buy, $53 PT On Gilead

In a note to clients today, Deutsche Bank reiterated a buy rating and $53 price target on biotech firm Gilead Sciences GILD. That's helping shares of Gilead crawl higher. The stock has recently been slammed following news of its $11 billion acquisition offer for Pharmasset VRUS. “Including Complera weekly growth in Q4, we believe HIV script trends are tracking $16.7M worse than consensus ($1,006.9M). Additionally, there is one day difference currently between 3Q11 (19 days of data) vs 18 days of data in 4Q11. We project that GILD HIV sales are about $10M/day. Truvada growth looks healthy while Atripla is decreasing week over week. We believe some of the week over week decreases in Atripla may be due to Complera weekly growth since its launch,” Deutsche Bank said in the note.